Program Schedule

226
Clostridium difficile: Treatment and Prevention

Saturday, October 11, 2014: 2:00 PM-3:30 PM
Room: The Pennsylvania Convention Center: 107-AB

Learning Objectives:

-

Target Audience: Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Epidemiologists, Clinicians

Tracks: Pediatric ID, Epidemiology and Infection Control, Adult ID

Moderators:  Erik Dubberke, MD, MSPH, Washington University School of Medicine and Deverick Anderson, MD, MPH, Duke University Medical Center

Presentations:
2:00 PM
1794
Appropriate Antibiotic Therapy is Associated with Reduced Risk of Community Acquired Clostridium difficile Infection
Ivy Y. Ge, Pharm. D. ; Carol Conell, Ph. D. ; Malika N. Kheraj, M. D. ; Alexander C. Flint, M. D., Ph. D. ; Darvin S. Smith, M.D., MSc
2:15 PM
1795
Above and Beyond Individual Exposure: Ward-level Antibiotic Prescribing Is the Principal Predictor of Increased Clostridium difficile Infection (CDI) Risk
Kevin Brown, MSc ; Nick Daneman, MD, MSc ; David N. Fisman, MD, MPH
2:30 PM
1796
Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients
Jennie H. Kwon, D.O. ; Kerry M. Bommarito, MPH ; Kimberly Reske, MPH ; Tiffany Hink, BS ; Sondra Seiler, BA ; Meghan Wallace, B.A. ; Carey-Ann D. Burnham, PhD ; Erik Dubberke, MD, MSPH
2:45 PM
1797
The Cost-Benefit of Federal Investment in Preventing Clostridium difficile Infections through the Use of a Multifaceted Infection Control and Antimicrobial Stewardship Program
Rachel Slayton, PhD, MPH ; James Baggs, PhD ; R. Douglas Scott, PhD ; Fernanda Lessa, MD ; L. Clifford Mcdonald, MD, FACP, FSHEA ; John Jernigan, MD, MS
3:00 PM
1798
Oral, Frozen Fecal Microbiota Capsules for Relapsing Clostridium difficile Infection
Ilan Youngster, M.D. ; George Russell, M.D. ; Christina Pindar ; Jenny Sauk, M.D. ; Elizabeth Hohmann, MD
3:15 PM
1799
Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
Paul Mariani, MD ; Connie S. Price, MD ; Robert Orenstein, DO ; Hill Harris, MD, MPH ; Mary Kay Sobcinski, RN, MHA

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

E. Dubberke, rebiotix: Consultant and Investigator, Consulting fee and Research support
sanofi pasteur: Consultant and Investigator, Consulting fee and Grant recipient
merck: Consultant and Grant Investigator, Consulting fee and Research support
cubist: Consultant and Investigator, Consulting fee and Research support

D. Anderson, None

See more of: Oral Abstract Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek